Alexandros Tsakalidis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alexandros Tsakalidis has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Christoforos Kosmidis
School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece
3 shared publications Stefanos Atmatzidis
Third Department of Surgery, AHEPA University Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece,
3 shared publications- Georgios Koimtzis
Department of General Surgery, Royal Glamorgan Hospital, Cardiff, UK
2 shared publications Isaac Kesisoglou
Third Department of Surgery, AHEPA University Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece,
2 shared publicationsKonstantinos Sapalidis
Third Department of Surgery, AHEPA University Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece,
2 shared publications- Paul Zarogoulidis
Pulmonary Department, General Clinic Euromedica, Thessaloniki, Greece
2 shared publications
Latest Publications
- Open Access
- 1 March 2019
- Published by Taylor & Francis in International Journal of General Medicine
- Vol. ume 12, 121-124
Management of low rectal gastrointestinal stromal tumor with neoadjuvant therapy and transanal excision: a rare case report and review of the literature
Background: Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract. However, rectal GISTs represent only 5% of this category. We report a case of a rectal GIST treated with local excision after neoadjuvant therapy. Case presentation: A 41-year-old male patient presented with anal bleeding. Colonoscopy revealed a mass located 5 cm from the anal verge. Histological examination showed a GIST with immunohistochemical positivity for CD117 and CD34. Transanal local excision was performed after neoadjuvant therapy. Conclusion: Neoadjuvant immunotherapy for GISTs with unfavorable localization may facilitate local excision and avoid complications of more demanding operations.
- 1 March 2019
- Published by Taylor & Francis in International Journal of General Medicine
- Vol. ume 12, 121-124
Open AccessManagement of low rectal gastrointestinal stromal tumor with neoadjuvant therapy and transanal excision: a rare case report and review of the literature
Background: Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract. However, rectal GISTs represent only 5% of this category. We report a case of a rectal GIST treated with local excision after neoadjuvant therapy. Case presentation: A 41-year-old male patient presented with anal bleeding. Colonoscopy revealed a mass located 5 cm from the anal verge. Histological examination showed a GIST with immunohistochemical positivity for CD117 and CD34. Transanal local excision was performed after neoadjuvant therapy. Conclusion: Neoadjuvant immunotherapy for GISTs with unfavorable localization may facilitate local excision and avoid complications of more demanding operations.
- Open Access
- 1 January 2019
- Published by Taylor & Francis in International Medical Case Reports Journal
- Vol. 12, 15-20
Transformation of ALK expression and PD-L1 0% to PD-L1 90% only after surgery: the need for rebiopsy in lung cancer patients
Lung cancer is still diagnosed at a late stage although novel diagnostic techniques are in use. However, as pharmacogenomics have evolved novel targeted therapies either with tyrosine kinase inhibitors or immunotherapy can be currently used as daily treatment. We present the case of a woman with anaplastic lymphoma-positive expression and programmed death-ligand 1 (PD-L1) 0% score upon diagnosis who underwent therapeutic surgery and represented PD-L1 90% expression, however, without anaplastic lymphoma kinase expression. Transformation of the tumor or new tumor is a question to be answered for this patient and possibly we should try and direct rebiopsies for this group of targeted therapy patients.
- 1 January 2019
- Published by Taylor & Francis in International Medical Case Reports Journal
- Vol. 12, 15-20
Open AccessTransformation of ALK expression and PD-L1 0% to PD-L1 90% only after surgery: the need for rebiopsy in lung cancer patients
Lung cancer is still diagnosed at a late stage although novel diagnostic techniques are in use. However, as pharmacogenomics have evolved novel targeted therapies either with tyrosine kinase inhibitors or immunotherapy can be currently used as daily treatment. We present the case of a woman with anaplastic lymphoma-positive expression and programmed death-ligand 1 (PD-L1) 0% score upon diagnosis who underwent therapeutic surgery and represented PD-L1 90% expression, however, without anaplastic lymphoma kinase expression. Transformation of the tumor or new tumor is a question to be answered for this patient and possibly we should try and direct rebiopsies for this group of targeted therapy patients.
- Open Access
- 1 January 2017
- Published by Ivyspring International Publisher in Journal of Biomedicine
- Vol. 2, 94-100
Melanoma from Molecular Pathways to Clinical Treatment: An Up to Date Review
Skin cancer is divided to melanoma and non-melanoma. Melanoma occurs due to deregulation of melanocytes. Melanoma is frequent in Caucasian population. During the last decade there is an increase in melanoma and in many cases there is a diagnostic challenge. Moreover; choosing the right treatment is a challenge for many patients. Malignant melanoma is known to be a lethal disease due to its aggressive capacity for metastasis and resistance to therapy. In the last decade, considerable efforts have gone into development of an effective immunotherapy for treatment of melanoma. The combination of macrophage activation and other treatments such as immunotherapy, surgery, chemotherapy, and radiotherapy, may provide an effective and comprehensive anti-melanoma strategy.
- 1 January 2017
- Published by Ivyspring International Publisher in Journal of Biomedicine
- Vol. 2, 94-100
Open AccessMelanoma from Molecular Pathways to Clinical Treatment: An Up to Date Review
Skin cancer is divided to melanoma and non-melanoma. Melanoma occurs due to deregulation of melanocytes. Melanoma is frequent in Caucasian population. During the last decade there is an increase in melanoma and in many cases there is a diagnostic challenge. Moreover; choosing the right treatment is a challenge for many patients. Malignant melanoma is known to be a lethal disease due to its aggressive capacity for metastasis and resistance to therapy. In the last decade, considerable efforts have gone into development of an effective immunotherapy for treatment of melanoma. The combination of macrophage activation and other treatments such as immunotherapy, surgery, chemotherapy, and radiotherapy, may provide an effective and comprehensive anti-melanoma strategy.